Kornimate/medical-research-clean huggingface dataset:
effectiveness and safety of thread embedding acupuncture for drug resistant epilepsy

Conditions: Epilepsy, Drug Resistant; Acupuncture Therapy

Summary: epilepsy is one of the most common neurological diseases all over the world. currently, about 70 million people have epilepsy worldwide. in particular, more than 30% of epilepsy patients still have seizures even though they are treated with appropriate anti-epileptic drugs (aeds). this number has remained unchanged even after more than 20 years with many new anti-epileptic drugs being introduced. according to international league against epilepsy (ilae), drug-resistant epilepsy is defined when a patient does not achieve seizure-free the seizure with two optimal antiepileptic drugs. this clinical trial is designed to evaluate the effectiveness and safety of thread-embedding acupuncture (tea) as palliative treatment of drug resistant epilepsy.

the objectives of this clinical trial are twofold: the effectiveness of tea is assessed by comparing the changes in the seizure control and quality of life at 5 months between 2 groups: the tea + baseline aeds group and the sham-tea (stea) + baseline aeds group. adverse events (aes) that occur during the study will be investigated to evaluate the safety of tea. this study is investigated by the following hypotheses: * tea can increase the probability of becoming seizure free. * tea can reduce the frequency and duration of seizures. * tea can improve quality of life. * tea is associated with adverse effects. this clinical trial will be performed as a 2-arm parallel design, randomized, controlled, assessor-blinded, clinical trial.

Eligibility criteria:
inclusion criteria: * people with drug resistant epilepsy * volunteers who agree to participate and sign the informed consent form, following a detailed explanation of clinical trials exclusion criteria: * under epilepsy surgery * inappropriate condition for thread-embedding acupuncture due to skin disease (the skin of the acupuncture point is swollen, hot, and red) or hemostatic disorder (pt inr (international normalized ratio )\> 2.0 or taking anticoagulant) * pregnant women or other inappropriate condition for thread-embedding acupuncture * other diseases that could affect or interfere with therapeutic outcomes, including body exhaustion, severe gastrointestinal disease, cardiovascular disease, hypertension, diabetes, renal disease, liver disease or thyroid disorder * tea within 6 months previous * psychiatric disorder currently undergoing treatment such as depression or schizophrenia * heavy drinking (more than 3 cups per day)

Keywords: drug resistant epilepsy thread embedding acupuncture
efficacy of nva237 compared to tiotropium in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and specific airway resistance in patients with moderate to severe copd.


Eligibility criteria:
inclusion criteria: * male or female adults aged ≥40 years * patients with moderate to severe copd defined by a post-bronchodilator forced expiratory volume in one second (fev1)/(fvc) forced vital capacity ratio of \<0.70 and a post-bronchodilator fev1 of ≤70% and fev1 ≥ 30% of predicted normal values. * current or ex-smokers who have a smoking history of at least 10 pack years. exclusion criteria: * pregnant or nursing (lactating) women * patients who have a clinically significant laboratory abnormality at run-in * patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment (gfr \<50 ml/min/1,732) or urinary retention. (bph patients who are stable on treatment can be considered). * patients with any history of asthma * patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation * patients receiving medications in the classes listed in the protocol as prohibited. other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd
effects of a minimal-contact lifestyle intervention on physical activity, diet, and body weight

Conditions: Weight Loss

Summary: the purpose of this study is to conduct a pilot randomized controlled trial, to determine whether providing financial incentives for meeting daily step goals (a) increases the daily step counts of participants, (b) increases compliance with the overall program (including diet recommendations), and (c) increases weight loss.


Eligibility criteria:
inclusion criteria: * required to be able to read. * required to have access to a computer. * required to have a body mass index between 27 and 45 kg.m-2. * required to take fewer than 7,000 steps per day at baseline (as determined by a pedometer, averaged across 4-7 days). exclusion criteria: * individuals who report having an injury or physical limitation that renders them unable to walk ¼ mile without difficulty. * uncontrolled cardiovascular or metabolic condition determined by health history questionnaire.
feasibility study of the microwave ablation system for lung tissue ablation

Conditions: Lung Neoplasm

Summary: evaluation of safety and technical feasibility of the phenowave mw ablation system for microwave ablation of lesions in the lung.

this study is a prospective, single-arm, single-center, study to evaluate the safety and technical feasibility of using the phenowave mw ablation system to deliver microwave energy for ablation of lesions in the lung.

Eligibility criteria:
inclusion criteria: * age 45-77 years at screening. * confirmed nsclc or solitary metastatic (oligometastatic) or pulmonary metastases from an extra thoracic primary tumor lung nodule through diagnostic biopsy * must be eligible for curative lung resection (lobectomy). * for primary tumor, pre-ablated parenchymal tumor/lesion size ≥ 20 mm if nsclc, or ≥ 10 mm for metastatic disease in diameter as measured from pre-operative ct image. * willing to participate in all aspects of study protocol for duration of study. * able to understand study requirements. * signs informed consent form. * boundary of tumor is at least 15 mm away from the pleura wall and/or fissure. exclusion criteria: * any contraindication to bronchoscopy, for example: * untreatable life-threatening arrhythmias. * inability to adequately oxygenate the patient during the procedure. * acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated). * recent myocardial infarction. * uncorrectable coagulopathy. * known coagulopathy. * platelet dysfunction or platelet count \< 100 x 109 cells/l or taking anticoagulant or antiplatelet agents that cannot be safely ceased in the opinion of the pulmonologist or surgeon. * history of major bleeding with bronchoscopy. * suspected pulmonary hypertension. * moderate-to-severe pulmonary fibrosis. * severe emphysema (gold iii/iv) or chronic obstructive pulmonary disease (copd) within 3cm of tumor/lesion boundary: prior copd assessment data is evaluated and pi consent is required. * bullae \>5 centimeter (cm) located in vicinity of target tumor/lesion. * any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic mwa, for example: * american society of anesthesiologists (asa) physical status classification \>p3 * stage 3 heart failure * severe cachexia * severe respiratory insufficiency or hypoxia * ongoing systemic infection. * contraindication to general anesthesia. * inability to stop anticoagulants (e.g., heparin, warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure. * participation in any other study in last 30 days. * breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study. * life expectancy of less than 6 months. * prior radiation therapy treatment in the target lobe. * implantable pacemaker or defibrillator.

Keywords: flexperc medical microwave ablation phenowave phenomapper
effects of unblocking the full potential of percept pc ipg

Conditions: Parkinson Disease

Summary: population size and eligible patients: the study will enroll patients with parkinson's disease (n=30) who had an ipg replacement from activa pc (older generation of neurostimulator) to medtronic percepttm pc (newer generation of neurostimulator) as a part of their standard-of-care. no patient will be receiving the system for research purposes only. study design: this is a prospective, double-blinded, randomized, cross-over clinical investigation to further investigate the efficiency of medtronic percepttm pc neurostimulator. this study involves three in clinic visits. during the first study visit, the patients' neurostimulator will be reprogrammed using all the additional features the percept pc has to offer. at the end of the visit, the patients will be randomized between their baseline program, ((activa pc group) and the newly defined programming settings (percept group). during the second visit (1-month follow-up) the effect will be clinically assessed, and a crossover of the condition will happen. the third visit (2-month follow-up) will be a follow-up visit with no programming but only clinical assessment. study duration: expected study duration is 1 year with the possibility for renewals. objectives and outcome measures: the goal is the study is to define whether or what the benefit is of the percept pc neurostimulator compared to the older activa pc neurostimulator. the primary outcome is patient-reported global impression of change (pgic). the secondary outcome measures are clinical scales assessing symptoms of parkinson's disease (updrs-iii and -iv) and quality of life (pdq-39), the active problems list and amount of medication intake.


Eligibility criteria:
inclusion criteria: * individuals with idiopathic parkinson's disease who previously underwent dbs surgery. * individuals who had ipg replacement from activa pc to medtronic percepttm pc neurostimulator as standard-of-care * individuals should be able to provide their informed consent exclusion criteria: * cognition impairment (moca \< 20/30) * patients with severe pd symptoms who are unable to come to the clinic three times within three months (e.g. bedridden patients)
molar sodium lactate filling in severe meningeal hemorrhage

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Summary: subarachnoid hemorrhage by aneurysmal rupture is a serious condition associated with a high mortality rate. among the complications presented by these patients, vasospasm is one of the main causes of secondary aggravation, in particular the appearance of delayed neurological deficits following the induced cerebral ischemia. classically occurring between the 4th and 12th day, with a peak on d7, its prevention is currently often ineffective. in recent years, many studies have shown that sodium lactate could be an interesting product for neuroprotection. in addition to an anti-osmotic effect that has been demonstrated by our team in the context of post-traumatic intracranial hypertension, a metabolic action has also been observed in periods of metabolic attacks induced by brain attacks. recently, a vasodilatory action of sodium lactate has been observed from an experimental and clinical point of view. the purpose of this work is to observe the effect of sodium lactate, compared to placebo, on cerebral hemodynamics measured by perfusion ct (mean transit time mtt) in a population of patients with hemorrhage under the arachnoid. this work is the preliminary work of a study that will investigate the potential preventive protective effect of sodium lactate on the incidence of vasospasm.


Eligibility criteria:
inclusion criteria: * any patient over 18 years of age with severe meningeal hemorrhage defined by a wfns≥3 score will be included in the study. * treated by endovascular embolization or surgically within 48 hours * after obtaining the informed consent of the patient, or his relatives if he is not searchable (coma). * affiliation to a social security system * after an adapted preliminary medical examination exclusion criteria: * post-traumatic meningeal hemorrhage * management time \>48h with respect to bleeding * known neurodegenerative pathology (alzheimer's, parkinson's, etc.), creutzfeldt-jacob disease * pregnant woman * decision not to treat * refusal to participate in the study * adult patient protected by law * person deprived of administrative or judicial freedom
efficacy of ergocalciferol in adults according to bmi

Conditions: Obesity; Vitamin D Deficiency

Summary: vitamin d insufficiency is an increasing trend in the united states. according to the nhanes data collection there was a near doubling of patients with vitamin d deficiency in 10 years. vitamin d deficiency is associated with several adverse outcomes such as increased fractures, certain microbial diseases, cardiovascular diseases, and metabolic dysfunction. the increasing prevalence of vitamin d deficiency has been attributed to the increasing prevalence of obesity. several studies have shown that obese patients have lower 25-oh vitamin d (25-ohd) levels compared to nonobese patients and obese patients require more vitamin d compared to nonobese patients. the most commonly prescribed medication to replete vitamin d deficiency is oral ergocalciferol. to date, no prospective trials have been published to evaluate a standard protocol in the treatment of vitamin d insufficiency in adults.


Eligibility criteria:
inclusion criteria: * study subjects have to be between the ages of 18 to 65 with a serum 25ohd level less than 20 ng/ml. exclusion criteria: * participants will be excluded if they have any of the following: 1. due to the inaccuracies of bmi in patients with increased muscle mass, in group with a bmi 25-35: men with a waist circumference \< 90 cm ; women \< 80 cm 2. chronic liver disease defined by any clinical or a history of serum ast or alt \> 2 times uln 3. kidney disease defined as a gfr \<60 ml/min 4. sarcoidosis 5. any known malignancy 6. known malabsorption disorder to include inflammatory bowel disease, celiac disease, cystic fibrosis, history of gastric bypass 7. primary hyperparathyroidism or hypercalcemia, 8. patients that are pregnant or considering pregnancy. 9. patients taking certain medications such as glucocorticoids, anti-seizure medications such has phenobarbital or phenytoin or patients taking antiviral medications for hiv as these are known to cause vitamin d deficiency 10. individuals excluded from having a dxa scan study participants will be excluded from having a dxa scan if any of the following: 1. any amputation of a extremity including toes 2. if they have a pacemaker, automatic defibrillator, coronary stents or metal suture material in the heart 3. if they have artificial joints, pins, plate or any other type of metal objects 4. if they have received contrast material such as barium in the past 7 days 5. if they have had a nuclear medicine study in the past 3 days
empatia@lecco- balance rehabilitation of autistic children with virtual reality

Conditions: Autism Spectrum Disorder

Summary: the general objective of this project is to investigate the possible efficacy of a training based on proprioceptive and visual feedback carried out with the grail (motekforce link) virtual reality environment on postural control and balance skills of school-aged children with clinical diagnosis of asd.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of asd * all participants were required to have estimated fsiq of 80 or above exclusion criteria: * using any stimulant or non-stimulant medication that affects the central nervous system * having an identified genetic disorder * having vision or hearing problems * suffering from chronic or acute medical illness * presence of epilepsy

Keywords: motor abilities
effect of baby massage on oral motor skills of premature babies

Conditions: Infant, Premature

Summary: this experimental research was conducted in a single-blind, block randomized controlled design type. the primary purpose of the study is to examine the effect of premature baby massage on oral motor coordination skills. the secondary aim is to evaluate the consistency of use of the oral feeding clinical scale in premature babies in turkey. as a result of the power analysis, baby massage was applied to the intervention group (n = 20) and oral stimulation with the fucile protocol was applied to the control group (n = 20). comparative results were evaluated statistically.

the effect of baby massage on oral motor coordination ability in prematures purpose: the primary purpose of the study is to examine the effect of premature baby massage on oral motor coordination skills. the secondary aim is to evaluate the consistency of use of the oral feeding clinical scale in premature babies in turkey. method: the research was a single-blind, block randomized controlled design type and data was collected between september 2021 and may 2023. baby massage was applied to the intervention group (n=20) of the study, and oral stimulation was applied with the fucile protocol to the control group (n=20). the applications were applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. feeding videos were evaluated by expert neonatal nurses using the oral feeding scale. descriptive statistical methods, fisher test, chi-square analysis, dependent and independent t test, mann whitney u test, one-way analysis of variance, kruskal wallis test, pearson and spearman correlations were used to evaluate the research results.

Eligibility criteria:
inclusion criteria: * being between 28-33 weeks of gestation, * not having a congenital disease, * clinical findings are stable and normal, * it meets the readiness criteria for oral feeding, * being fed at full dose via oral/nasogastric tube and having never attempted oral intake before, * it must weigh between 1000-2000 grams * parents give their consent to participate in the research and record video. exclusion criteria: * premature babies of parents who did not give consent to participate in the study, * premature babies of parents who gave up participating in the study at any stage of the study, * physiological stability was impaired during the data collection process; premature babies who require oxygen support and/or mechanical respirators, * conditions that disrupt clinical stability such as intracranial bleeding, necrotizing enterocolitis, neonatal sepsis are included in the process.

Keywords: oral feeding skills baby massage fucile protocol
effect of irradiation of the cavernous sinus and the sellar region on autobiographical memory

Conditions: Cavernous Sinus Meningioma; Pituitary Adenoma

Summary: several studies showed that radiotherapy as brain tumors treatment may affect cognition. it was observed that durable memory impairments could arise at irradiated patients if radiotherapy is applied on medial temporal lobes. however, results concerned studies of anterograde memory and none, this day, estimates the impact of radiotherapy on autobiographical memory which also involves hippocampus. the aim of this study is to evaluate effects of cavernous sinus or sellar region irradiation on autobiographical memory. thirty 35 to 65 years old patients, with cavernous sinus meningioma or pituitary adenoma for who radiotherapy is indicated will be recruited.

several studies showed that radiotherapy as brain tumors treatment may affect cognition. it was observed that durable memory impairments could arise at irradiated patients if radiotherapy is applied on medial temporal lobes. however, results concerned studies of anterograde memory and none, this day, estimates the impact of radiotherapy on autobiographical memory which also involves hippocampus, as specified in nadel and moscovitch model, the multiple trace theory. autobiographical memory impairment issue is fundamental for identity construction. prevent those impairments is important to quality of life improvement after such treatments. the aim of this study is to evaluate effects of cavernous sinus or sellar region irradiation on autobiographical memory. a pilot study was conducted with 10 patients affected by left cavernous sinus meningioma divided in two groups: the first one with untreated patients and the second one with patients who received cavernous sinus irradiation between 2 and 5 years before pilot study. this study indicated autobiographical memory deterioration in two groups and a worsening in treated group. study limits did not allow us to draw conclusions. that is why, sample size will be extended and patients with cavernous sinus meningioma or pituitary adenoma will be recruited because of proximity between cavernous sinus, pituitary gland and hippocampus. investigators wish to recruit 30 patients with cavernous sinus and meningioma. investigators hope for confirm our results from pilot study.

Eligibility criteria:
inclusion criteria: * age between 35 and 65. * patient with: * meningioma of the cavernous sinus for which radiotherapy is planned * or a pituitary adenoma for which radiotherapy is planned * french mother tongue * person affiliated to national insurance * person who give its verbal agreement to participate exclusion criteria: * presence of a serious psychiatric disorder (major depression, psychotic disorders, etc.) and central nervous system disease (epilepsy, multiple sclerosis, etc.). * treatment with chemotherapy * general intellectual abilities deficient (iq \<80) * extension front of their meningioma * deficient language skills.

Keywords: cavernous sinus meningioma pituitary adenoma hippocampus irradiation autobiographical memory
treatment of mild to moderate distal subungual onychomycosis of the toenail

Conditions: Onychomycosis

Summary: the purpose of the study is to determine whether nb002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

the purpose of the study is to determine whether nb002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

Eligibility criteria:
inclusion criteria: * are healthy males or females between the ages of 18 and 75 years of age; * have a clinical diagnosis of mild to moderate dso in the nail of at least one great toe, involving 25%-67% of the nail, without lunular or proximal involvement; * positive mycology results (ie, koh test and culture of a dermatophyte) from the target great toenail; * refrain from using any lotions, creams, liquids, or polish on treated toenails or on the skin immediately adjacent to the toenails during the treatment period unless directed to do so by the investigator; * are willing to refrain from using topical steroids or topical antifungals on toenails or the skin immediately adjacent to the toenails; or systemic antifungals for the duration of the study; exclusion criteria: * females who are pregnant, plan to become pregnant during the study, or are nursing a child; * are hypersensitive to topical creams, ointments, medications, or surfactants; * have received systemic antifungal therapy for any reason within 3 months, or topical antifungal therapy on the toenails or skin immediately adjacent to the toenails within 3 weeks prior to the start of the study; or * have taken any investigational drug within 4 weeks prior to the start of the study. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic persistent infection of the nail bed or plate